156 related articles for article (PubMed ID: 7922196)
1. Methods of controlling hyperphosphatemia in patients with chronic renal failure.
Llach F; Nikakhtar B
Curr Opin Nephrol Hypertens; 1993 May; 2(3):365-71. PubMed ID: 7922196
[TBL] [Abstract][Full Text] [Related]
2. The clinical management of hyperphosphatemia.
Ritz E
J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
[TBL] [Abstract][Full Text] [Related]
3. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
Malluche HH; Monier-Faugere MC
Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemia and phosphate binders.
Schucker JJ; Ward KE
Am J Health Syst Pharm; 2005 Nov; 62(22):2355-61. PubMed ID: 16278327
[TBL] [Abstract][Full Text] [Related]
5. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia.
Savica V; Calò LA; Caldarera R; Cavaleri A; Granata A; Santoro D; Savica R; Muraca U; Mallamace A; Bellinghieri G
Nephron Physiol; 2007; 105(3):p52-5. PubMed ID: 17220638
[TBL] [Abstract][Full Text] [Related]
6. Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure.
Neves KR; Graciolli FG; dos Reis LM; Pasqualucci CA; Moysés RM; Jorgetti V
Kidney Int; 2004 Dec; 66(6):2237-44. PubMed ID: 15569312
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
Qunibi WY; Nolan CR
Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
[TBL] [Abstract][Full Text] [Related]
8. [A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis].
Borrego J; Pérez del Barrio P; Serrano P; García Cortés MJ; Sánchez Perales MC; Borrego FJ; Liébana A; Gil Cunquero JM; Pérez Bañasco V
Nefrologia; 2000; 20(4):348-54. PubMed ID: 11039260
[TBL] [Abstract][Full Text] [Related]
9. Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD).
Qunibi WY
Kidney Int Suppl; 2004 Sep; (90):S8-S12. PubMed ID: 15296501
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
Delmez JA; Slatopolsky E
Am J Kidney Dis; 1992 Apr; 19(4):303-17. PubMed ID: 1562018
[TBL] [Abstract][Full Text] [Related]
11. Is there increasing evidence to change the management of renal bone disease?
Harum P
Nephrol News Issues; 1999 Apr; 13(4):55-6. PubMed ID: 10418451
[No Abstract] [Full Text] [Related]
12. New developments in the management of hyperphosphatemia in chronic kidney disease.
McIntyre CW
Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of hyperphosphatemia in chronic renal failure].
Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
[No Abstract] [Full Text] [Related]
14. Hyperphosphatemia among end-stage renal disease patients in developing countries: a forgotten issue?
Afifi A; El-Sayed H; El-Setouhi M; Ahmed H; Khalifa N
Hemodial Int; 2005 Oct; 9(4):409-15. PubMed ID: 16219062
[TBL] [Abstract][Full Text] [Related]
15. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
16. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
Takahashi Y; Tanaka A; Nakamura T; Fukuwatari T; Shibata K; Shimada N; Ebihara I; Koide H
Kidney Int; 2004 Mar; 65(3):1099-104. PubMed ID: 14871431
[TBL] [Abstract][Full Text] [Related]
18. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
19. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
20. [Acute hyperphosphatemia secondary to phosphate administration for bowel preparation].
Gutiérrez E; González E; Hernández E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Praga M
Nefrologia; 2004; 24(3):283-7. PubMed ID: 15283320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
